{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T19:54:14Z","timestamp":1789761254726,"version":"4.0.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T00:00:00Z","timestamp":1666051200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T00:00:00Z","timestamp":1666051200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2020YFC2008304"],"award-info":[{"award-number":["2020YFC2008304"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Crit Care"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Evidence supports therapeutic drug monitoring of polymyxin B, but clinical data for establishing an area under the concentration\u2013time curve across 24\u00a0h at steady state (AUC<jats:sub>ss,24\u00a0h<\/jats:sub>) threshold are still limited. This study aimed to examine exposure\u2013response\/toxicity relationship for polymyxin B to establish an AUC<jats:sub>ss,24\u00a0h<\/jats:sub> threshold in a real-world cohort of patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Using a validated Bayesian approach to estimate AUC<jats:sub>ss,24\u00a0h<\/jats:sub> from two samples, AUC<jats:sub>ss,24\u00a0h<\/jats:sub> threshold that impacted the risk of polymyxin B-related nephrotoxicity and clinical response were derived by classification and regression tree (CART) analysis and validated by Cox regression analysis and logical regression analysis.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 393 patients were included; acute kidney injury (AKI) was 29.0%, clinical response was 63.4%, and 30-day all-cause mortality was 35.4%. AUC<jats:sub>ss,24\u00a0h<\/jats:sub> thresholds for AKI of\u2009&gt;\u200999.4\u00a0mg\u00a0h\/L and clinical response of\u2009&gt;\u200945.7\u00a0mg\u00a0h\/L were derived by CART analysis. Cox and logical regression analyses showed that AUC<jats:sub>ss,24\u00a0h<\/jats:sub> of\u2009&gt;\u2009100\u00a0mg\u00a0h\/L was a significant predictor of AKI (HR 16.29, 95% CI 8.16\u201330.25, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) and AUC<jats:sub>ss,24\u00a0h<\/jats:sub> of\u2009\u2265\u200950\u00a0mg\u00a0h\/L (OR 4.39, 95% CI 2.56\u20137.47, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) was independently associated with clinical response. However, these exposures were not associated with mortality. In addition, the correlation between trough concentration (1.2\u20132.8\u00a0mg\/L) with outcomes was similar to AUC<jats:sub>ss,24\u00a0h<\/jats:sub>.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>For critically ill patients, AUC<jats:sub>ss,24\u00a0h<\/jats:sub> threshold of 50\u2013100\u00a0mg\u00a0h\/L was associated with decreased nephrotoxicity while assuring clinical efficacy. Therapeutic drug monitoring is recommended for individualizing polymyxin B dosing.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13054-022-04195-7","type":"journal-article","created":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T10:03:13Z","timestamp":1666087393000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["An area under the concentration\u2013time curve threshold as a predictor of efficacy and nephrotoxicity for individualizing polymyxin B dosing in patients with carbapenem-resistant gram-negative bacteria"],"prefix":"10.1186","volume":"26","author":[{"given":"Jing","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaohua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingli","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tongwen","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peile","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,18]]},"reference":[{"issue":"6","key":"4195_CR1","doi-asserted-by":"publisher","first-page":"711","DOI":"10.2217\/fmb.13.39","volume":"8","author":"T Velkov","year":"2013","unstructured":"Velkov T, Roberts KD, Nation RL, Thompson PE, Li J. Pharmacology of polymyxins: new insights into an \u2018old\u2019 class of antibiotics. Future Microbiol. 2013;8(6):711\u201324.","journal-title":"Future Microbiol"},{"issue":"4","key":"4195_CR2","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","volume":"28","author":"M Paul","year":"2022","unstructured":"Paul M, Carrara E, Retamar P, T\u00e4ngd\u00e9n T, Bitterman R, Bonomo RA, et al. European society of clinical microbiology and infectious diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant gram-negative bacilli (endorsed by European society of intensive care medicine). Clin Microbiol Infect. 2022;28(4):521\u201347.","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"4195_CR3","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1128\/AAC.02634-15","volume":"60","author":"MH Rigatto","year":"2016","unstructured":"Rigatto MH, Oliveira MS, Perdig\u00e3o-Neto LV, Levin AS, Carrilho CM, Tanita MT, et al. Multicenter prospective cohort study of renal failure in patients treated with colistin versus polymyxin B. Antimicrob Agents Ch. 2016;60(4):2443\u20139.","journal-title":"Antimicrob Agents Ch"},{"issue":"7","key":"4195_CR4","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1007\/s00134-017-4780-6","volume":"43","author":"T T\u00e4ngd\u00e9n","year":"2017","unstructured":"T\u00e4ngd\u00e9n T, Ramos Mart\u00edn V, Felton T, Nielsen EI, Marchand S, Br\u00fcggemann RJ, et al. The role of infection models and PK\/PD modelling for optimising care of critically ill patients with severe infections. Intensive Care Med. 2017;43(7):1021\u201332.","journal-title":"Intensive Care Med"},{"issue":"4","key":"4195_CR5","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1093\/cid\/cit334","volume":"57","author":"AM Sandri","year":"2013","unstructured":"Sandri AM, Landersdorfer CB, Jacob J, Boniatti MM, Dalarosa MG, Falci DR, et al. Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens. Clin Infect Dis. 2013;57(4):524\u201331.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"4195_CR6","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.ijantimicag.2016.09.010","volume":"48","author":"TB Tran","year":"2016","unstructured":"Tran TB, Velkov T, Nation RL, Forrest A, Tsuji BT, Bergen PJ, et al. Pharmacokinetics\/pharmacodynamics of colistin and polymyxin B: Are we there yet? Int J Antimicrob Ag. 2016;48(6):592\u20137.","journal-title":"Int J Antimicrob Ag"},{"issue":"1","key":"4195_CR7","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/phar.2209","volume":"39","author":"BT Tsuji","year":"2019","unstructured":"Tsuji BT, Pogue JM, Zavascki AP, Paul M, Daikos GL, Forrest A, et al. International consensus guidelines for the optimal use of the polymyxins: endorsed by the American college of clinical pharmacy (ACCP), European society of clinical microbiology and infectious diseases (ESCMID), infectious diseases society of America (IDSA), international society for anti-infective pharmacology (ISAP), society of critical care medicine (SCCM), and society of infectious diseases pharmacists (SIDP). Pharmacotherapy. 2019;39(1):10\u201339.","journal-title":"Pharmacotherapy"},{"issue":"9","key":"4195_CR8","first-page":"e523","volume":"71","author":"MJ Satlin","year":"2020","unstructured":"Satlin MJ, Lewis JS, Weinstein MP, Jean P, Humphries RM, Gunnar K, et al. Clinical and laboratory standards institute and European committee on antimicrobial susceptibility testing position statements on polymyxin B and colistin clinical breakpoints. Clin Infect Dis. 2020;71(9):e523\u20139.","journal-title":"Clin Infect Dis"},{"issue":"7","key":"4195_CR9","doi-asserted-by":"publisher","first-page":"e00483","DOI":"10.1128\/AAC.00483-18","volume":"62","author":"EA Lakota","year":"2018","unstructured":"Lakota EA, Landersdorfer CB, Nation RL, Li J, Kaye KS, Rao GG, et al. Personalizing polymyxin B dosing using an adaptive feedback control algorithm. Antimicrob Agents Ch. 2018;62(7):e00483-e418.","journal-title":"Antimicrob Agents Ch"},{"issue":"1","key":"4195_CR10","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/phar.2207","volume":"39","author":"S Alosaimy","year":"2019","unstructured":"Alosaimy S, Jorgensen SC, Rybak MJ. The optimal use of the polymyxins before their time is up. Pharmacotherapy. 2019;39(1):7\u20139.","journal-title":"Pharmacotherapy"},{"issue":"4","key":"4195_CR11","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.ijantimicag.2013.12.002","volume":"43","author":"FF Tuon","year":"2014","unstructured":"Tuon FF, Rigatto MH, Lopes CK, Kamei LK, Rocha JL, Zavascki AP. Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium. Int J Antimicrob Ag. 2014;43(4):349\u201352.","journal-title":"Int J Antimicrob Ag"},{"issue":"5","key":"4195_CR12","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.cmi.2020.12.009","volume":"27","author":"F Wagenlehner","year":"2021","unstructured":"Wagenlehner F, Lucenteforte E, Pea F, Soriano A, Tavoschi L, Steele VR, et al. Systematic review on estimated rates of nephrotoxicity and neurotoxicity in patients treated with polymyxins. Clin Microbiol Infect. 2021;27(5):671\u201386.","journal-title":"Clin Microbiol Infect"},{"key":"4195_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.105328","volume":"163","author":"M Sisay","year":"2021","unstructured":"Sisay M, Hagos B, Edessa D, Tadiwos Y, Mekuria AN. Polymyxin-induced nephrotoxicity and its predictors: a systematic review and meta-analysis of studies conducted using RIFLE criteria of acute kidney injury. Pharmacol Res. 2021;163: 105328.","journal-title":"Pharmacol Res"},{"key":"4195_CR14","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1186\/s12967-021-03111-x","volume":"19","author":"XJ Zhang","year":"2021","unstructured":"Zhang XJ, Qi SY, Duan XG, Han B, Zhang SG, Liu SH, et al. Clinical outcomes and safety of polymyxin B in the treatment of carbapenem-resistant gram-negative bacterial infections: a real-world multicenter study. J Transl Med. 2021;19:431.","journal-title":"J Transl Med"},{"issue":"4","key":"4195_CR15","doi-asserted-by":"publisher","first-page":"231","DOI":"10.21037\/atm-22-236","volume":"10","author":"N Chen","year":"2022","unstructured":"Chen N, Guo J, Xie J, Xu M, Hao X, Ma K, et al. Population pharmacokinetics of polymyxin B: a systematic review. Ann Transl Med. 2022;10(4):231.","journal-title":"Ann Transl Med"},{"issue":"2","key":"4195_CR16","first-page":"e01900","volume":"62","author":"PL Wang","year":"2021","unstructured":"Wang PL, Zhang QW, Zhu ZF, Pei H, Feng M, Sun TW, et al. Comparing population pharmacokinetics and acute kidney injury of polymyxin B in Chinese patients with and without renal insufficiency. Antimicrob Agents Ch. 2021;62(2):e01900-01920.","journal-title":"Antimicrob Agents Ch"},{"issue":"5","key":"4195_CR17","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1111\/crj.13493","volume":"16","author":"Q Ye","year":"2022","unstructured":"Ye Q, Wang Q, Chen Z, Chen W, Zhan Q, Wang C. Effectiveness, nephrotoxicity, and therapeutic drug monitoring of polymyxin B in nosocomial pneumonia among critically ill patients. Clin Respir J. 2022;16(5):402\u201312.","journal-title":"Clin Respir J"},{"issue":"3","key":"4195_CR18","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1111\/bcp.15061","volume":"88","author":"L Han","year":"2022","unstructured":"Han L, Xu FM, Zhang XS, Zhang CH, Dai Y, Zhou ZY, et al. Trough polymyxin B plasma concentration is an independent risk factor for its nephrotoxicity. Br J Clin Pharmacol. 2022;88(3):1202\u201310.","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"4195_CR19","first-page":"1591","volume":"11","author":"Y Deng","year":"2022","unstructured":"Deng Y, Gu JY, Li X, Tong H, Guo SW, Xu B, et al. Does monitoring total and free polymyxin B1 plasma concentrations predict polymyxin B-induced nephrotoxicity? A retrospective study in critically ill patients. Infect Dis Ther. 2022;11(4):1591\u2013608.","journal-title":"Infect Dis Ther"},{"issue":"6","key":"4195_CR20","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s00134-020-06050-1","volume":"46","author":"MH Abdul-Aziz","year":"2020","unstructured":"Abdul-Aziz MH, Alffenaar JWC, Bassetti M, Bracht H, Dimopoulos G, Marriott D, et al. Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position paper. Intensive Care Med. 2020;46(6):1127\u201353.","journal-title":"Intensive Care Med"},{"key":"4195_CR21","unstructured":"EUCAST. European Committee on antimicrobial susceptibility testing breakpoint tables for interpretation of MICs and zone diameters. Version 7.1. In. 2017."},{"issue":"8656","key":"4195_CR22","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/S0140-6736(89)90381-4","volume":"334","author":"M Larvin","year":"1989","unstructured":"Larvin M, Mcmahon MJ. APACHE-II score for assessment and monitoring of acute pancreatitis. Lancet. 1989;334(8656):201\u20135.","journal-title":"Lancet"},{"issue":"11","key":"4195_CR23","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1097\/00003246-199811000-00016","volume":"26","author":"JL Vincent","year":"1998","unstructured":"Vincent JL, De Mendon\u00e7a A, Cantraine F, Moreno R, Takala J, Suter PM, et al. Use of the SOFA score to assess the incidence of organ dysfunction\/failure in intensive care units: results of a multicenter, prospective study. Crit Care Med. 1998;26(11):1793\u2013800.","journal-title":"Crit Care Med"},{"key":"4195_CR24","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1016\/j.cmi.2015.11.004","volume":"22","author":"X Guan","year":"2016","unstructured":"Guan X, He L, Hu B, Hu J, Huang X, Lai G, et al. Laboratory diagnosis, clinical management and infection control of the infections caused by extensively drug-resistant gram-negative bacilli: a Chinese consensus statement. Clin Microbiol Infect. 2016;22:S15\u201325.","journal-title":"Clin Microbiol Infect"},{"key":"4195_CR25","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1097\/FTD.0000000000000754","volume":"42","author":"PL Wang","year":"2020","unstructured":"Wang PL, Zhang QW, Qin ZF, Xing H, Xu M, Pei H, et al. A simple and robust LC-MS\/MS analytical method for therapeutic drug monitoring of plasma and cerebrospinal fluid polymyxin B1 and B2. Ther Drug Monit. 2020;42:716\u201323.","journal-title":"Ther Drug Monit"},{"key":"4195_CR26","doi-asserted-by":"publisher","first-page":"829","DOI":"10.3389\/fphar.2020.00829","volume":"11","author":"PL Wang","year":"2020","unstructured":"Wang PL, Zhang QW, Zhu ZF, Feng M, Sun TW, Yang J, et al. Population pharmacokinetics and limited sampling strategy for therapeutic drug monitoring of polymyxin B in Chinese patients with multidrug-resistant Gram-negative bacterial infections. Front Pharmacol. 2020;11:829.","journal-title":"Front Pharmacol"},{"issue":"2 SUPPL. 1","key":"4195_CR27","first-page":"i-ii+S1-S266","volume":"39","author":"AS Levey","year":"2002","unstructured":"Levey AS, Coresh J, Bolton K, Culleton B, Harvey KS, Ikizler TA, et al. K\/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 SUPPL. 1):i-ii+S1-S266.","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"4195_CR28","doi-asserted-by":"publisher","first-page":"c179","DOI":"10.1159\/000339789","volume":"120","author":"A Khwaja","year":"2012","unstructured":"Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract. 2012;120(4):c179-184.","journal-title":"Nephron Clin Pract"},{"key":"4195_CR29","first-page":"95","volume":"77","author":"W Chen","year":"2021","unstructured":"Chen W, Liu H, Wang Q, Wang X, Kong X, Wang X, et al. Estimation of the area under concentration-time curve of polymyxin B based on limited sampling concentrations in Chinese patients with severe pneumonia. Eur J Pharm Sci. 2021;77:95\u2013105.","journal-title":"Eur J Pharm Sci"},{"issue":"6","key":"4195_CR30","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1093\/cid\/ciaa303","volume":"71","author":"MJ Rybak","year":"2020","unstructured":"Rybak MJ, Le J, Lodise TP, Levine DP, Bradley JS, Liu C, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American society of health-system pharmacists, the infectious diseases society of America, the pediatric infectious diseases society, and the society of infectious diseases pharmacists. Clin Infect Dis. 2020;71(6):1361\u20134.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"4195_CR31","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1002\/cpt.2202","volume":"109","author":"SG Wicha","year":"2021","unstructured":"Wicha SG, M\u00e4rtson AG, Nielsen EI, Koch BC, Friberg LE, Alffenaar JW, et al. From therapeutic drug monitoring to model-informed precision dosing for antibiotics. Clin Pharmacol Ther. 2021;109(4):928\u201341.","journal-title":"Clin Pharmacol Ther"},{"key":"4195_CR32","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.addr.2014.05.016","volume":"77","author":"MP Pai","year":"2014","unstructured":"Pai MP, Neely M, Rodvold KA, Lodise TP. Innovative approaches to optimizing the delivery of vancomycin in individual patients. Adv Drug Deliv Rev. 2014;77:50\u20137.","journal-title":"Adv Drug Deliv Rev"},{"issue":"5","key":"4195_CR33","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1093\/jac\/dku561","volume":"70","author":"MH Rigatto","year":"2015","unstructured":"Rigatto MH, Behle TF, Falci DR, Freitas T, Lopes NT, Nunes M, et al. Risk factors for acute kidney injury (AKI) in patients treated with polymyxin B and influence of AKI on mortality: a multicentre prospective cohort study. J Antimicrob Chemoth. 2015;70(5):1552\u20137.","journal-title":"J Antimicrob Chemoth"},{"key":"4195_CR34","doi-asserted-by":"publisher","first-page":"96","DOI":"10.3390\/antibiotics11010096","volume":"11","author":"T Ueda","year":"2022","unstructured":"Ueda T, Takesue Y, Nakajima K, Ichiki K, Ishikawa K, Yamada K, et al. Validation of vancomycin area under the concentration-time curve estimation by the Bayesian approach using one-point samples for predicting clinical outcomes in patients with methicillin-resistant Staphylococcus aureus infections. Antibiotics. 2022;11:96.","journal-title":"Antibiotics"},{"issue":"4","key":"4195_CR35","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.cmi.2019.10.029","volume":"26","author":"B Dalton","year":"2020","unstructured":"Dalton B, Rajakumar I, Langevin A, Ondro C, Sabuda D, Griener T, et al. Vancomycin area under the curve to minimum inhibitory concentration ratio predicting clinical outcome: a systematic review and meta-analysis with pooled sensitivity and specificity. Clin Microbiol Infect. 2020;26(4):436\u201346.","journal-title":"Clin Microbiol Infect"},{"issue":"10","key":"4195_CR36","doi-asserted-by":"publisher","first-page":"e675","DOI":"10.1093\/cid\/ciaa1354","volume":"72","author":"TJ Dilworth","year":"2021","unstructured":"Dilworth TJ, Schulz LT, Rose WE. Vancomycin advanced therapeutic drug monitoring: Exercise in futility or virtuous endeavor to improve drug efficacy and safety? Clin Infec Dis. 2021;72(10):e675\u201381.","journal-title":"Clin Infec Dis"},{"key":"4195_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2020.610604","volume":"11","author":"Y Zhu","year":"2021","unstructured":"Zhu Y, Jia P, Zhou M, Zhang J, Zhang G, Kang W, et al. Evaluation of the clinical systems for polymyxin susceptibility testing of clinical Gram-negative bacteria in China. Front Microbiol. 2021;11: 610604.","journal-title":"Front Microbiol"},{"issue":"Supplement_7","key":"4195_CR38","doi-asserted-by":"publisher","first-page":"S565","DOI":"10.1093\/cid\/ciz830","volume":"69","author":"Y Doi","year":"2019","unstructured":"Doi Y. Treatment options for carbapenem-resistant gram-negative bacterial infections. Clin Infec Dis. 2019;69(Supplement_7):S565\u201375. https:\/\/doi.org\/10.1093\/cid\/ciz830.","journal-title":"Clin Infec Dis"}],"container-title":["Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-022-04195-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13054-022-04195-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-022-04195-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T15:07:29Z","timestamp":1674659249000},"score":1,"resource":{"primary":{"URL":"https:\/\/ccforum.biomedcentral.com\/articles\/10.1186\/s13054-022-04195-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,18]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["4195"],"URL":"https:\/\/doi.org\/10.1186\/s13054-022-04195-7","relation":{},"ISSN":["1364-8535"],"issn-type":[{"value":"1364-8535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,18]]},"assertion":[{"value":"9 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committees of the First Affiliated Hospital of Zhengzhou University (2020-KY-0318) and waived informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have consented to the publication of the present manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"320"}}